OLD GREENWICH, Conn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (Nasdaq: STRR and STRRP) (“Star” or the “Company”), a diversified holding company, announced today that its wholly owned subsidiary, Hudson RPO, operating inside its Business Services division, has rebranded to Hudson Talent Solutions (“HTS”), reflecting the business’ broadened vision and expanded global capabilities. The rebrand is accompanied by the launch of a new website, www.hudsontalent.com. The change is the culminati ...

Determined that Wellspect will Deliver Greater Financial and Strategic Benefits to Stockholders as Part of the CompanyCHARLOTTE, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company has completed the evaluation of strategic alternatives for its Wellspect Healthcare business (“Wellspect”), which was announced in February 2025. As a part of its review process, Dentsply Sirona considered a range of potential opportuni ...

Spain site opens with two R/R AML subjects enrolled; One treated On track to recruit 45 subjects in 4Q25 for initial data unblinding HOUSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced that it has enrolled the first two subjects, and treated one, in the European Union (EU) in its pivotal Phase 2B/3, ...

Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter Company seeks alignment on reasonable path forward for Zynquista NDA resubmission FDA feedback from Type D meeting expected by end of September THE WOODLANDS, Texas, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the Company has submitted additional clinical data to the U.S. Food and Drug Adminis ...

NEW PORT RICHEY, Fla., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Zeo Energy Corp. (Nasdaq: ZEO) (“Zeo,” “Zeo Energy,” or the “Company”), a Florida-based provider of residential solar and commercial long-duration energy-storage solutions, today announced that the Company will be presenting at ROTH Capital’s 12th Annual Solar & Storage Symposium on Tuesday, September 9, at the upcoming RE+ trade show in Las Vegas, Nevada, which runs from September 8-11, 2025. The symposium, hosted by ROTH Capital during RE+, provide ...

VANCOUVER, British Columbia, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath testing devices is pleased to report its participation in the NSC Safety Congress & Expo, taking place September 15–17, 2025 in Denver, Colorado. The NSC Safety Congress & Expo is the world’s largest annual event dedicated to workplace safety, health, and environmental professionals and will have thousan ...

Core Viewpoint - Lifeward Ltd. has received CE mark approval for the ReWalk 7 Personal Exoskeleton, allowing for its commercial sale in the European Union, which is expected to drive revenue growth and market adoption in Europe [1][2]. Company Overview - Lifeward is a global leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities, with a mission to drive innovation in rehabilitation and recovery [3]. - The company has a diverse portfolio that includes the ReWalk Exoskeleton, AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System, and operates in the United States, Israel, and Germany [3]. Product Details - The ReWalk 7 features advancements such as cloud connectivity, push-button control, customizable walking speeds, and seamless activation for stairs and curbs, enhancing user experience for individuals with spinal cord injuries [2]. - The European market, particularly Germany, is significant for Lifeward, representing approximately 40% of its exoskeleton sales, with established reimbursement processes for personal exoskeletons [1][2]. Market Position - Lifeward GmbH serves as the primary sales force in Europe, with Germany being the second largest market for ReWalk personal exoskeletons globally [2]. - The company has established supply contracts with major insurance carriers in Germany, facilitating reimbursement for about 45% of individuals with statutory health insurance coverage [2].

BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it has made a $5 million strategic minority equity investment in Talphera, Inc. (Nasdaq: TLPH), acquiring 9,090,909 shares at an at-market price of $0.55 per share as part of Talphera’s concurrently announced private placement financing. Talphera expec ...

BELVIDERE, NJ, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic, and sustainable produce and products, today announced it will showcase its innovative, award-winning Kick. Sports Nutrition line, recently recognized as the 2025 Sports Nutrition Product of the Year by the Mindful Awards, at ECRM’s Vitamin, Weight Management & Sports Nutrition Session, taking p ...

Kennewick, WA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) announced new data demonstrating the exceptional precision of its proprietary Precision Radionuclide Therapy (RadioGel® for human therapies and IsoPet® for veterinary applications) Advancing Targeted Cancer Therapies The therapeutic ratio is the amount of radiation delivered to a tumor compared to surrounding healthy tissue and is a critical measure of treatment precision. A high therapeutic ratio minimizes collateral damage while ma ...